Court upholds Teva on BMS Baraclude generic; GSK sees good pediatric data for Promacta; Lupin unleashes generic Cipro;

@FiercePharma: Vivus hits Actavis with Qsymia patent-infringement lawsuit. Story | Follow @FiercePharma

@TracyStaton: Trending at FiercePharmaMarketing: Do reps push drugs off-label? Study says yes. Does it work? Also yes. More | Follow @TracyStaton

@EricPFierce: Biolyse is back in production with paclitaxel after a re-inspection by Health Canada cleared its plant. News | Follow @EricPFierce

@CarlyHFierce: With patent extension up for grabs, Shire agrees to test Vyvanse in preschoolers. More | Follow @CarlyHFierce

@JustinHFierce: New Pet Pace med device monitors temp and vitals, marketed for owners and vets like an e-dog-whisperer. Article | Follow @JustinHFierce

> Teva Pharmaceuticals Industries ($TEVA) said that an appeals court has upheld its challenge to the patent on Bristol-Myers Squibb's ($BMS) hepatitis B drug Baraclude and will launch its version in the U.S. as soon as it gets final approval from the FDA. Release

> GlaxoSmithKline ($GSK) reported new promising Phase II clinical data for hep C drug Promacta/Revolade in pediatric patients. Release

> Some hedge fund managers think contingent value rights could rekindle the Pfizer ($PFE), AstraZeneca ($AZN) talks but others say no. Story

> India's Lupin has begun making a generic version of Bayer's Cipro for the U.S. market and has a 180 exclusivity on the product. Story

> The U.K.'s National Health System has a new software tool to help providers determine how much access their patients have to the drugs they need. Story

> Novartis ($NVS) has come out with its pig antibiotic Florvio for swine respiratory disease, a fast-acting solution that farmers can put in their livestock's water. Release

Medical Device News

@FierceMedDev: Chrono Therapeutics snares $32M in Series A money for wearable smoking cessation device. More | Follow @FierceMedDev

@StacyALawrence: Mobile medical app brings laboratory testing to the home. Story | Follow @StacyALawrence

@MichaelGFierce: UCSB study: New silver nanoparticles dissolve if they don't hit their mark. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: C.R. Bard wins unanimous FDA panel vote for drug-eluting balloon catheter. Article | Follow @EmilyWFierce

> World's tiniest blood glucose monitor launches for iPhone, Android. More

> Medtronic scores FDA approval for TAVR in high-risk patients. Story

> With stroke of genius from a plunger, new med device cuts costs for healing wounds. Item

Biotech News

@FierceBiotech: This week's Chutes & Ladders: CEO John Johnson jumps ship as Dendreon sinks lower. Report | Follow @FierceBiotech

@JohnCFierce: I have no idea if Porges will be successful, but it's damn good fun to report on it. | Follow @JohnCFierce

@DamianFierce: Break up Amgen Pt. II: Analyst says its moonshot R&D approach is bad for business. Story | Follow @DamianFierce

@EmilyMFierce: Think tank: $4.5B investment in BRAIN Initiative too modest. More | Follow @EmilyMFierce

> With early data looming, Celgene grabs rights to Agios' leukemia drug. Story

> OncoMed hits the brakes on cancer studies after troubling safety signs. News

> Could the cunning use of CVRs save a Pfizer-AstraZeneca merger? Item

And Finally... Japanese regulators report that there were 306 violations by retailers in online sales of over-the-counter drugs in the first 24 hours after the country lifted a ban on Internet sales. Story

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.